Genmab A/S Files Procedural 6-K with SEC
Ticker: GNMSF · Form: 6-K · Filed: Aug 13, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Aug 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, procedural, registration-statement
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K, just a procedural update, no new info.
AI Summary
Genmab A/S filed a Form 6-K on August 13, 2024, to be incorporated by reference into its existing S-8 registration statements. The filing does not contain new financial information or operational updates but serves a procedural purpose for its SEC filings.
Why It Matters
This filing is a routine administrative update for Genmab A/S, ensuring its registration statements remain current with the SEC. It does not signal new business developments or financial performance.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not contain any new financial or operational information that would impact the company's risk profile.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-012039 (filing_id) — Accession Number
- August 13, 2024 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form S-8 (document) — Incorporated by Reference
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8, serving a procedural update to SEC filings.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on August 13, 2024.
Does this filing contain new financial results or operational updates for Genmab A/S?
No, this filing is a procedural report and does not contain new financial results or operational updates.
Which registration statements will this 6-K filing be incorporated into?
This filing will be incorporated into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is the principal executive office address for Genmab A/S as listed in the filing?
The address of the principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-08-13 14:57:34
Filing Documents
- tmb-20240813x6k.htm (6-K) — 19KB
- tmb-20240813xex99d1.htm (EX-99.1) — 25KB
- tmb-20240813xex99d2.htm (EX-99.2) — 50KB
- tmb-20240813xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240813xex99d2001.jpg (GRAPHIC) — 5KB
- 0001558370-24-012039.txt ( ) — 108KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: AUGUST 13, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated August 13, 2024: Capital Increase in Genmab as a Result of Employee Warrant Exercise 99.2 Company Announcement Dated August 13, 2024: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons